TDS Pharm Q1 2026: Revenue up 53%, Net Profit surges 213%

Revenue KRW 8.07B (vs KRW 5.28B YoY, +53%), Net profit KRW 1.15B (vs KRW 0.37B YoY, +213%), EPS KRW 217 (vs KRW 69)
Debt-to-equity ratio 41.15% (vs 26.57% at year-end 2025), short-term borrowings KRW 13.8B (vs KRW 7.6B)
Cash & cash equivalents KRW 3.3B, short-term financial products KRW 25B; ample liquidity
R&D expenses KRW 0.15B (1.83% of sales) continued investment
One lawsuit as plaintiff, but limited financial impact
No dividend paid, no share buyback or cancellation